For patients whose B-CLL cells do not show increased CDC with the rituximab-CFH mAb combination, the addition of antibodies against mCRPs including CD59 might lead to induction of CDC and increased cellular cytotoxicity. This evidence concerns the gene CD59 and B-cell chronic lymphocytic leukemia.